Free Trial

National Vision (EYE) Competitors

National Vision logo
$18.65 -0.73 (-3.77%)
Closing price 05/21/2025 04:00 PM Eastern
Extended Trading
$18.66 +0.01 (+0.03%)
As of 05/21/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EYE vs. GKOS, NARI, INSP, IRTC, BLCO, TMDX, SLNO, NVST, PRCT, and LIVN

Should you be buying National Vision stock or one of its competitors? The main competitors of National Vision include Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), PROCEPT BioRobotics (PRCT), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

National Vision vs.

National Vision (NASDAQ:EYE) and Glaukos (NYSE:GKOS) are both consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, community ranking, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

National Vision currently has a consensus price target of $17.75, suggesting a potential downside of 4.83%. Glaukos has a consensus price target of $134.67, suggesting a potential upside of 41.78%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than National Vision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Vision
0 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.44
Glaukos
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

In the previous week, National Vision had 10 more articles in the media than Glaukos. MarketBeat recorded 20 mentions for National Vision and 10 mentions for Glaukos. Glaukos' average media sentiment score of 1.43 beat National Vision's score of 1.18 indicating that Glaukos is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
National Vision
13 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Glaukos
9 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

99.0% of Glaukos shares are held by institutional investors. 2.7% of National Vision shares are held by insiders. Comparatively, 5.8% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

National Vision has a net margin of -0.81% compared to Glaukos' net margin of -39.04%. National Vision's return on equity of 3.52% beat Glaukos' return on equity.

Company Net Margins Return on Equity Return on Assets
National Vision-0.81% 3.52% 1.39%
Glaukos -39.04%-16.53%-10.61%

Glaukos received 199 more outperform votes than National Vision when rated by MarketBeat users. Likewise, 65.19% of users gave Glaukos an outperform vote while only 64.50% of users gave National Vision an outperform vote.

CompanyUnderperformOutperform
National VisionOutperform Votes
258
64.50%
Underperform Votes
142
35.50%
GlaukosOutperform Votes
457
65.19%
Underperform Votes
244
34.81%

National Vision has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

National Vision has higher revenue and earnings than Glaukos. National Vision is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
National Vision$1.85B0.80-$65.90M-$0.33-56.52
Glaukos$404.52M13.42-$134.66M-$2.37-40.08

Summary

Glaukos beats National Vision on 10 of the 18 factors compared between the two stocks.

Get National Vision News Delivered to You Automatically

Sign up to receive the latest news and ratings for EYE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EYE vs. The Competition

MetricNational VisionOphthalmic goods IndustryStaples SectorNASDAQ Exchange
Market Cap$1.47B$10.58B$17.53B$8.39B
Dividend YieldN/A0.96%3.05%4.10%
P/E Ratio-93.2534.1616.3019.71
Price / Sales0.803.094.59117.39
Price / Cash7.0314.5316.3934.62
Price / Book1.762.586.174.50
Net Income-$65.90M$224.27M$737.42M$248.18M
7 Day Performance0.27%2.67%-0.39%0.20%
1 Month Performance62.46%17.26%3.16%12.37%
1 Year Performance21.42%-18.31%-2.76%7.04%

National Vision Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EYE
National Vision
2.7623 of 5 stars
$18.65
-3.8%
$17.75
-4.8%
+18.0%$1.47B$1.85B-93.2514,000Positive News
Analyst Forecast
Gap Up
GKOS
Glaukos
4.6206 of 5 stars
$94.57
+5.1%
$134.67
+42.4%
-12.5%$5.40B$404.52M-32.95780Positive News
NARI
Inari Medical
0.5708 of 5 stars
$79.97
flat
$69.22
-13.4%
N/A$4.68B$493.63M-59.24800
INSP
Inspire Medical Systems
4.672 of 5 stars
$156.54
+3.5%
$211.91
+35.4%
-4.0%$4.62B$840.11M90.49760Positive News
IRTC
iRhythm Technologies
1.2686 of 5 stars
$137.80
+0.1%
$128.55
-6.7%
+52.9%$4.40B$618.59M-37.861,790Positive News
BLCO
Bausch + Lomb
4.1389 of 5 stars
$11.91
+5.6%
$15.50
+30.2%
-22.8%$4.21B$4.83B-13.0812,500Gap Up
TMDX
TransMedics Group
1.4381 of 5 stars
$118.73
+6.5%
$126.70
+6.7%
-12.4%$4.02B$488.23M126.31210Positive News
SLNO
Soleno Therapeutics
4.8514 of 5 stars
$76.70
-0.1%
$106.78
+39.2%
+65.6%$3.87BN/A-23.1030News Coverage
Positive News
NVST
Envista
4.1759 of 5 stars
$18.56
+5.5%
$20.08
+8.2%
-9.2%$3.15B$2.50B-2.8612,700Positive News
Gap Up
PRCT
PROCEPT BioRobotics
2.9275 of 5 stars
$54.44
+2.5%
$90.00
+65.3%
-17.6%$3.01B$249.12M-27.92430Positive News
Gap Up
LIVN
LivaNova
3.7979 of 5 stars
$45.23
+2.7%
$59.17
+30.8%
-27.9%$2.47B$1.28B107.692,900Positive News
Analyst Upgrade
High Trading Volume

Related Companies and Tools


This page (NASDAQ:EYE) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners